Veracyte Shares Slip After Sales Guidance Narrows

What happened

Veracyte narrowed its full-year revenue outlook to $590 million–$593 million from $590 million–$596 million, reflecting lower-than-expected volumes of some tests. Testing revenue guidance fell to $571 million–$573 million from $576 million–$582 million. The company also expects minimal revenue from its recently launched tests.

Confirmed

Global impact / market context

The lower testing outlook indicates that fewer tests are expected to generate revenue than management previously anticipated. If volumes remain weak, Veracyte could bring in less sales revenue, while limited contributions from newly launched tests leave less near-term growth to offset that shortfall.

Analyst inference

The article reports a sharp after-hours share decline alongside the lower outlook, although shares were still up 24% through Wednesday’s close. The gap between those figures highlights a sudden change in trading expectations, not a confirmed longer-term direction for the stock.

Confirmed

What to watch

1. Check future company updates for Decipher Prostate test volumes, which management said were below expectations, and whether the reported shortfall continues to weigh on testing revenue. Analyst inference
2. Compare subsequent full-year revenue guidance with the revised $590 million–$593 million range to see whether management raises, maintains, or lowers its sales expectations. Analyst inference
3. Watch for reported revenue from recently launched tests; Veracyte expects minimal contribution, so stronger sales could add revenue while weaker uptake would leave that support limited. Confirmed

Evidence

• Original source link unavailable